JP2005510473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510473A5 JP2005510473A5 JP2003531986A JP2003531986A JP2005510473A5 JP 2005510473 A5 JP2005510473 A5 JP 2005510473A5 JP 2003531986 A JP2003531986 A JP 2003531986A JP 2003531986 A JP2003531986 A JP 2003531986A JP 2005510473 A5 JP2005510473 A5 JP 2005510473A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- cycloalkyl
- alkyl
- alkylidene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 23
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 18
- 229910052736 halogen Inorganic materials 0.000 description 15
- 150000002367 halogens Chemical group 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 150000002431 hydrogen Chemical class 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 125000003107 substituted aryl group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- -1 C 1-8 -alkyl Chemical group 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical group C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical group C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical group C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 0 C***1c2ccccc2*(*)C1* Chemical compound C***1c2ccccc2*(*)C1* 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008403 visual deficit Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32675401P | 2001-10-02 | 2001-10-02 | |
| PCT/US2002/031308 WO2003028650A2 (en) | 2001-10-02 | 2002-09-30 | Benzimidazolidinone derivatives as muscarinic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005510473A JP2005510473A (ja) | 2005-04-21 |
| JP2005510473A5 true JP2005510473A5 (enExample) | 2006-01-05 |
| JP4347047B2 JP4347047B2 (ja) | 2009-10-21 |
Family
ID=23273560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003531986A Expired - Fee Related JP4347047B2 (ja) | 2001-10-02 | 2002-09-30 | ムスカリン作用薬としてのベンゾイミダゾリジノン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US7087593B2 (enExample) |
| EP (1) | EP1432420B1 (enExample) |
| JP (1) | JP4347047B2 (enExample) |
| KR (2) | KR100809569B1 (enExample) |
| CN (1) | CN1561212A (enExample) |
| AR (1) | AR036716A1 (enExample) |
| AT (1) | ATE516030T1 (enExample) |
| AU (1) | AU2002327810B2 (enExample) |
| BR (1) | BR0213611A (enExample) |
| CA (1) | CA2457647A1 (enExample) |
| MX (1) | MXPA04003103A (enExample) |
| NO (1) | NO20041317L (enExample) |
| NZ (1) | NZ531550A (enExample) |
| RU (1) | RU2288919C2 (enExample) |
| TW (1) | TWI310034B (enExample) |
| WO (1) | WO2003028650A2 (enExample) |
| ZA (1) | ZA200402609B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2288919C2 (ru) * | 2001-10-02 | 2006-12-10 | Акадиа Фармасьютикалз, Инк. | Производные бензимидазолидинона в качестве агентов мускариновых рецепторов |
| US6951849B2 (en) | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| AU2003222738B2 (en) * | 2002-05-07 | 2009-09-17 | Neurosearch A/S | Novel azacyclic ethynyl derivatives |
| CN1777425A (zh) * | 2003-03-28 | 2006-05-24 | 阿卡蒂亚药品公司 | 用于疼痛控制的毒蕈碱性m1受体激动剂 |
| US7157471B2 (en) * | 2003-08-25 | 2007-01-02 | Boehringer Ingelheim International Gmbh | Haloalkyl- and piperidine-substituted benzimidazole-derivatives |
| AR045843A1 (es) * | 2003-10-03 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EA016286B1 (ru) * | 2005-09-30 | 2012-03-30 | Глэксо Груп Лимитед | Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине |
| WO2007036711A1 (en) * | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
| EP1960389B1 (en) * | 2005-09-30 | 2012-08-15 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP1973904A2 (en) * | 2005-12-27 | 2008-10-01 | University Of Toledo | Muscarinic agonists and methods of use thereof |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| GB0607949D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| TW200813018A (en) * | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
| GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
| JP2010539218A (ja) * | 2007-09-20 | 2010-12-16 | グラクソ グループ リミテッド | Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用 |
| WO2009037294A1 (en) * | 2007-09-20 | 2009-03-26 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| AU2008335135A1 (en) | 2007-12-11 | 2009-06-18 | Cytopathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| JP2011520905A (ja) | 2008-05-15 | 2011-07-21 | ザ・ユニバーシティ・オブ・トレド | 向知性剤としてのムスカリンアゴニスト |
| US20100158829A1 (en) * | 2008-12-24 | 2010-06-24 | Conopco, Inc., D/B/A Unilever | Method and Composition for Color Modulation |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20100286136A1 (en) * | 2009-05-08 | 2010-11-11 | Simon Jones | Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders |
| KR101594002B1 (ko) | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체 |
| US9549928B2 (en) | 2011-04-29 | 2017-01-24 | The University Of Toledo | Muscarinic agonists as enhancers of cognitive flexibility |
| JP6393524B2 (ja) * | 2014-06-05 | 2018-09-19 | ロート製薬株式会社 | 保湿剤 |
| WO2016022644A1 (en) * | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| CN107848972B (zh) | 2015-07-20 | 2021-06-18 | 阿卡蒂亚药品公司 | 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法 |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| US20190117636A1 (en) * | 2016-03-29 | 2019-04-25 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
| EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| WO2018200977A1 (en) | 2017-04-28 | 2018-11-01 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| WO2019046167A1 (en) | 2017-08-30 | 2019-03-07 | Acadia Pharmaceuticals Inc. | PIMAVANSERIN FORMULATIONS |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CR20220565A (es) | 2020-05-06 | 2023-01-13 | Merck Sharp & Dohme Llc | Inhibidores de il4i1 y métodos de uso |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2024138108A2 (en) * | 2022-12-22 | 2024-06-27 | University Of Florida Research Foundation, Incorporated | Metabolically stable sigma receptor ligands |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH407121A (de) | 1962-03-30 | 1966-02-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen Piperidinderivaten |
| US4371388A (en) * | 1980-01-25 | 1983-02-01 | Monsanto Company | 3-Substituted aminoalkyl-2-benzothiazolinones as plant growth regulants |
| US4254127A (en) * | 1980-04-03 | 1981-03-03 | Janssen Pharmaceutica, N.V. | 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives |
| US4943580A (en) * | 1987-03-09 | 1990-07-24 | Janssen Pharmaceutica N.V. | Anti-histaminic benzimidazole, imidazopyridine and purine derivatives |
| GB8718345D0 (en) * | 1987-08-03 | 1987-09-09 | Fordonal Sa | N-substituted benzamides |
| US4861889A (en) * | 1988-03-14 | 1989-08-29 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(2,3,4,5,6-pentafluorophenoxy)-8-azabicyclo[3.2.1]octanes |
| IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| JP3916092B2 (ja) | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬 |
| JP3916093B2 (ja) | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | 光学活性イミダゾリジノン誘導体とその製造方法 |
| AU701127B2 (en) * | 1994-10-27 | 1999-01-21 | Merck & Co., Inc. | Muscarine antagonists |
| KR19980703192A (ko) * | 1995-03-22 | 1998-10-15 | 우에하라아끼라 | 티아졸 유도체 |
| WO1997016187A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| US5756508A (en) | 1995-10-31 | 1998-05-26 | Merck & Co., Inc. | Muscarine antagonists |
| WO1997016192A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| AU7478396A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine agonists |
| US5718912A (en) | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
| WO1999032481A1 (en) | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US6569956B1 (en) | 1999-12-22 | 2003-05-27 | Basf Corporation | Hyperbranched polyol macromolecule, method of making same, and coating composition including same |
| KR100879647B1 (ko) | 2000-03-06 | 2009-01-20 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
| TWI310035B (en) | 2000-04-28 | 2009-05-21 | Acadia Pharm Inc | Muscarinic agonists |
| DE60123643T2 (de) | 2000-09-19 | 2007-08-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Benzimidazolonderivate mit affinität zu serotonin- und dopaminrezeptoren |
| US6586435B2 (en) * | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| RU2288919C2 (ru) * | 2001-10-02 | 2006-12-10 | Акадиа Фармасьютикалз, Инк. | Производные бензимидазолидинона в качестве агентов мускариновых рецепторов |
| US6951849B2 (en) * | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
-
2002
- 2002-09-30 RU RU2004113451/04A patent/RU2288919C2/ru not_active IP Right Cessation
- 2002-09-30 NZ NZ531550A patent/NZ531550A/en not_active IP Right Cessation
- 2002-09-30 JP JP2003531986A patent/JP4347047B2/ja not_active Expired - Fee Related
- 2002-09-30 MX MXPA04003103A patent/MXPA04003103A/es active IP Right Grant
- 2002-09-30 BR BR0213611-2A patent/BR0213611A/pt not_active IP Right Cessation
- 2002-09-30 AT AT02763824T patent/ATE516030T1/de not_active IP Right Cessation
- 2002-09-30 CA CA002457647A patent/CA2457647A1/en not_active Abandoned
- 2002-09-30 TW TW091122574A patent/TWI310034B/zh not_active IP Right Cessation
- 2002-09-30 AU AU2002327810A patent/AU2002327810B2/en not_active Ceased
- 2002-09-30 KR KR1020067025160A patent/KR100809569B1/ko not_active Expired - Fee Related
- 2002-09-30 KR KR10-2004-7004720A patent/KR20040047877A/ko not_active Ceased
- 2002-09-30 CN CNA028194446A patent/CN1561212A/zh active Pending
- 2002-09-30 WO PCT/US2002/031308 patent/WO2003028650A2/en not_active Ceased
- 2002-09-30 US US10/262,517 patent/US7087593B2/en not_active Expired - Fee Related
- 2002-09-30 EP EP02763824A patent/EP1432420B1/en not_active Expired - Lifetime
- 2002-10-02 AR ARP020103714A patent/AR036716A1/es unknown
-
2004
- 2004-03-30 NO NO20041317A patent/NO20041317L/no not_active Application Discontinuation
- 2004-04-01 ZA ZA200402609A patent/ZA200402609B/en unknown
-
2006
- 2006-05-03 US US11/418,342 patent/US7273857B2/en not_active Expired - Fee Related
- 2006-07-19 US US11/490,416 patent/US20060258707A1/en not_active Abandoned
-
2007
- 2007-09-20 US US11/858,828 patent/US20080009520A1/en not_active Abandoned
- 2007-11-27 US US11/945,857 patent/US20080070948A1/en not_active Abandoned
-
2010
- 2010-05-07 US US12/776,096 patent/US20100216840A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1926719B1 (en) | 2-aniline-4-aryl substituted thiazole derivatives | |
| RU2004113451A (ru) | Производные бензимидазолидинона в качестве агентов мускариновых рецепторов | |
| NZ595829A (en) | 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives | |
| JP2007529486A5 (enExample) | ||
| NO20076418L (no) | Heterocyclic compounds as agonists for the thyroid receptor | |
| JP2009532464A5 (enExample) | ||
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2014526549A5 (enExample) | ||
| JP2009542716A5 (enExample) | ||
| NZ594332A (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| JP2014526435A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| TW200635904A (en) | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | |
| JP2011506501A5 (enExample) | ||
| JP2019505595A5 (enExample) | ||
| RU2015116816A (ru) | Производное имидазола | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| CA2598536A1 (en) | Oxyindole derivatives as 5ht4 receptor agonists | |
| NO20085271L (no) | Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni | |
| NZ596154A (en) | Cyclic compound having substituted phenyl group | |
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| JP2010535858A5 (enExample) | ||
| JP2004507527A5 (enExample) | ||
| RU2014144951A (ru) | Новое 1-замещенное производное индазола |